UNITED STATES
                       SECURITIES AND EXCHANGE COMMISSION
                             Washington, D.C. 20549

                                    FORM 8-K

                                 CURRENT REPORT

     Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

         Date of Report (date of earliest event reported): June 28, 2017

                               CEL-SCI CORPORATION
                        ---------------------------------
             (Exact name of Registrant as specified in its charter)



          Colorado                       01-11889               84-0916344
  ------------------------          -----------------        ----------------
(State or other jurisdiction      (Commission File No.)     (IRS Employer
     of incorporation)                                       Identification No.)


                         8229 Boone Boulevard, Suite 802
                             Vienna, Virginia 22182
                        ---------------------------------
          (Address of principal executive offices, including Zip Code)


       Registrant's telephone number, including area code: (703) 506-9460

                                       N/A
                        ---------------------------------
          (Former name or former address if changed since last report)

Check appropriate box below if the Form 8-K filing is intended to simultaneously
satisfy  the filing  obligation  of the  registrant  under any of the  following
provisions (see General Instruction A.2. below)

[] Written communications pursuant to Rule 425 under the Securities Act (17
   CFR 230.425)

[] Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
   240.14a-12)

[] Pre-commencement communications pursuant to Rule 14d-2(b) under the
   Exchange Act (17 CFR 240.14d-2(b))

[] Pre-commencement communications pursuant to Rule 13e-14(c) under the
   Exchange Act (17 CFR 240.13e-4(c))

<PAGE>

Item 8.01   Other Events

     On June 28, 2017 CEL-SCI  Corporation  received a letter from the U.S. Food
and Drug Administration  (FDA) in response to CEL-SCI's most recent June 2, 2017
submission regarding the clinical hold imposed on the Company's Phase 3 head and
neck cancer study with Multikine (Leukocyte  Interleukin,  Inj.) Investigational
New Drug (IND).

     In this most recent letter, the FDA requested that three additional changes
be made to the Multikine  Investigator  Brochure (IB) that CEL-SCI  submitted to
the FDA on June 2, 2017. The FDA provided instructions directing CEL-SCI on what
the specific  changes should be.  CEL-SCI  intends to swiftly make the requested
changes to the IB and submit its  response to the FDA as soon as possible  after
the July 4 holiday. The FDA did not raise any other hold issues in this letter.

     CEL-SCI  was  also  told by the FDA that  the  effect  of the hold is not a
termination of the study.  The only action that CEL-SCI needed to be aware of is
that CEL-SCI may not enroll new patients and may not resume  Multikine dosing in
any previously  enrolled patient in this study or initiate any new studies under
this IND. CEL-SCI is not currently planning to do any of these things.

     Nine hundred  twenty-eight  (928) head and neck cancer  patients  have been
enrolled and have completed  treatment in the Phase 3 study.  In accordance with
the study protocol,  the FDA's  instructions,  and subject to the clinical hold,
CEL-SCI  continues  to follow these  patients  and gather all  protocol-specific
data.  In light of new  clinical  information  from  the  Phase 3 study  CEL-SCI
decided  in April 2017 that it was not  necessary  to add more  patients  to the
study and therefore withdrew the study amendment for additional patients.

     The study  endpoint  is a 10%  increase  in overall  survival  of  patients
between  the two main  comparator  groups  in favor of the group  receiving  the
Multikine  treatment  regimen.  The  determination if the study end point is met
will occur when there are a total of 298 deaths in those two groups.

                                       2
<PAGE>

                                   SIGNATURES


     Pursuant to the  requirements  of the Securities  Exchange Act of 1934, the
registrant  has duly  caused  this  report  to be  signed  on its  behalf by the
undersigned hereunto duly authorized.

Date: June 29, 2017

                                      CEL-SCI CORPORATION


                                      By: /s/ Geert R. Kersten
                                          -----------------------------
                                          Geert R. Kersten
                                          Chief Executive Officer
[{"type": "8-K", "sequence": "1", "filename": "form8kitem801fdajune-17.txt", "description": "FORM 8-K ITEM 8.01 FDA", "secsgml_size_bytes": 4737}]
{"company-data": {"conformed-name": "CEL SCI CORP", "cik": "0000725363", "assigned-sic": "2836", "irs-number": "840916344", "state-of-incorporation": "CO", "fiscal-year-end": "0930"}, "filing-values": {"form-type": "8-K", "act": "34", "file-number": "001-11889", "film-number": "17938980"}, "business-address": {"street1": "8229 BOONE BLVD .", "street2": "SUITE 802", "city": "VIENNA", "state": "VA", "zip": "22182", "phone": "7035069460"}, "mail-address": {"street1": "8229 BOONE BLVD.", "street2": "SUITE 802", "city": "VIENNA", "state": "VA", "zip": "22182"}, "former-company": {"former-conformed-name": "INTERLEUKIN 2 INC", "date-changed": "19880317"}}
UNITED STATES
                       SECURITIES AND EXCHANGE COMMISSION
                             Washington, D.C. 20549

                                    FORM 8-K

                                 CURRENT REPORT

     Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

         Date of Report (date of earliest event reported): June 28, 2017

                               CEL-SCI CORPORATION
                        ---------------------------------
             (Exact name of Registrant as specified in its charter)

          Colorado                       01-11889               84-0916344
  ------------------------          -----------------        ----------------
(State or other jurisdiction      (Commission File No.)     (IRS Employer
     of incorporation)                                       Identification No.)

                         8229 Boone Boulevard, Suite 802
                             Vienna, Virginia 22182
                        ---------------------------------
          (Address of principal executive offices, including Zip Code)

       Registrant's telephone number, including area code: (703) 506-9460

                                       N/A
                        ---------------------------------
          (Former name or former address if changed since last report)

Check appropriate box below if the Form 8-K filing is intended to simultaneously
satisfy  the filing  obligation  of the  registrant  under any of the  following
provisions (see General Instruction A.2. below)

[] Written communications pursuant to Rule 425 under the Securities Act (17
   CFR 230.425)

[] Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
   240.14a-12)

[] Pre-commencement communications pursuant to Rule 14d-2(b) under the
   Exchange Act (17 CFR 240.14d-2(b))

[] Pre-commencement communications pursuant to Rule 13e-14(c) under the
   Exchange Act (17 CFR 240.13e-4(c))
Item 8.01   Other Events

     On June 28, 2017 CEL-SCI  Corporation  received a letter from the U.S. Food
and Drug Administration  (FDA) in response to CEL-SCI's most recent June 2, 2017
submission regarding the clinical hold imposed on the Company's Phase 3 head and
neck cancer study with Multikine (Leukocyte  Interleukin,  Inj.) Investigational
New Drug (IND).

     In this most recent letter, the FDA requested that three additional changes
be made to the Multikine  Investigator  Brochure (IB) that CEL-SCI  submitted to
the FDA on June 2, 2017. The FDA provided instructions directing CEL-SCI on what
the specific  changes should be.  CEL-SCI  intends to swiftly make the requested
changes to the IB and submit its  response to the FDA as soon as possible  after
the July 4 holiday. The FDA did not raise any other hold issues in this letter.

     CEL-SCI  was  also  told by the FDA that  the  effect  of the hold is not a
termination of the study.  The only action that CEL-SCI needed to be aware of is
that CEL-SCI may not enroll new patients and may not resume  Multikine dosing in
any previously  enrolled patient in this study or initiate any new studies under
this IND. CEL-SCI is not currently planning to do any of these things.

     Nine hundred  twenty-eight  (928) head and neck cancer  patients  have been
enrolled and have completed  treatment in the Phase 3 study.  In accordance with
the study protocol,  the FDA's  instructions,  and subject to the clinical hold,
CEL-SCI  continues  to follow these  patients  and gather all  protocol-specific
data.  In light of new  clinical  information  from  the  Phase 3 study  CEL-SCI
decided  in April 2017 that it was not  necessary  to add more  patients  to the
study and therefore withdrew the study amendment for additional patients.

     The study  endpoint  is a 10%  increase  in overall  survival  of  patients
between  the two main  comparator  groups  in favor of the group  receiving  the
Multikine  treatment  regimen.  The  determination if the study end point is met
will occur when there are a total of 298 deaths in those two groups.

                                       2
SIGNATURES

     Pursuant to the  requirements  of the Securities  Exchange Act of 1934, the
registrant  has duly  caused  this  report  to be  signed  on its  behalf by the
undersigned hereunto duly authorized.

Date: June 29, 2017

                                      CEL-SCI CORPORATION

                                      By: /s/ Geert R. Kersten
                                          -----------------------------
                                          Geert R. Kersten
                                          Chief Executive Officer